Lemtrada 12mg Infusion 1.2ml is an immunosuppressive and anti-inflammatory medicine, classified as a monoclonal antibody, containing the active ingredient Alemtuzumab. It is primarily used to treat relapsing forms of multiple sclerosis (MS) in adults and, in some cases, to manage certain types of leukaemia (such as chronic lymphocytic leukaemia, CLL) or for immune system suppression before transplant procedures.

While Lemtrada 12mg Infusion 1.2ml does not cure multiple sclerosis or leukaemia, it helps to slow the progression of the disease, reduce relapse frequency, and manage immune-related damage. This medication works by targeting and destroying immune cells that are thought to attack healthy tissues, thereby rebalancing the immune response.

This medicine is administered under medical supervision as an intravenous infusion. Due to its strong immunosuppressive effects, it is typically given in treatment cycles, and patients are closely monitored before, during, and after each injection.

Lemtrada 12mg Infusion 1.2ml is used in the treatment of the following:

• Relapsing-Remitting Multiple Sclerosis (RRMS)

• Chronic Lymphocytic Leukaemia (CLL)

• Pre-transplant Conditioning (off-label use)

Lemtrada 12mg Infusion 1.2ml contains alemtuzumab, a medicine that targets and removes certain white blood cells that are overactive in diseases like multiple sclerosis and leukaemia. These cells can damage healthy parts of the body by reducing them.

Before starting Lemtrada 12mg Infusion 1.2ml, inform your doctor about all the medicines you take, including prescription drugs, over-the-counter medicines, vitamins, and herbal supplements. Some medications, such as phenobarbital, Phenytoin, Efavirenz, and St. John’s Wort, can interact with Lemtrada 12mg Infusion 1.2ml and may cause side effects or reduce its effectiveness. Your doctor may need to adjust your treatment or monitor you closely. Avoid starting or stopping any medicine without medical advice during this treatment

• Keep out of sight and reach of pets and children

• Store protected from light at a temperature not exceeding 30°C.

Lemtrada 12mg Infusion 1.2ml is given through an intravenous (IV) infusion by a healthcare professional, not taken by mouth. It is administered in treatment cycles as decided by your doctor. Regular monitoring is needed during and after treatment. Do not miss or delay doses without medical advice, and follow your doctor’s instructions closely.

Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them.

Serious side effects of Lemtrada 12mg Infusion 1.2ml are:

• Severe infections (e.g., pneumonia, urinary tract infections, viral reactivation)

• Autoimmune reactions (e.g., thyroid disorders, kidney problems)

• Infusion-related reactions (chest pain, drop in blood pressure, breathing difficulty)

• Liver problems (yellowing of skin or eyes, dark urine)

• Bleeding or bruising easily (due to low platelets)

• Neurological issues (confusion, vision changes, weakness in limbs)

• Risk of certain cancers (rare but possible with long-term use)

Common side effects of Lemtrada 12mg Infusion 1.2ml are:

• Headache

• Fever or chills

• Nausea and vomiting

• Rash or itching

• Tiredness or weakness

• Back pain or joint pain

• Difficulty sleeping

• Mouth or throat pain

• Cough or shortness of breath

• Low white blood cell counts (may increase infection risk)

1. Take only under medical supervision: Alemtuzumab must be given in a hospital or clinic due to the risk of serious immune-related side effects.

2. Attend all follow-up tests: Regular blood and urine tests (up to 4 years) are essential to monitor for delayed side effects.

3. Use reliable contraception: Women should avoid pregnancy during treatment and for at least 4 months after the last dose.

4. Report signs of infection: Contact your doctor if you develop fever, cough, or sore throat, as the immune system may be weakened.

5. Avoid live vaccines: Do not take live or weakened vaccines unless advised by your doctor during and after treatment.